Total Payments
$966,121
2024 Payments
$61,830
Companies
54
Transactions
1,574
Medicare Patients
8,634
Medicare Billing
$738,652
Payment Breakdown by Category
Other$452,477 (46.8%)
Research$292,379 (30.3%)
Consulting$151,103 (15.6%)
Travel$39,259 (4.1%)
Food & Beverage$30,331 (3.1%)
Education$573.09 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $444,777 | 178 | 46.0% |
| Unspecified | $292,379 | 92 | 30.3% |
| Consulting Fee | $151,103 | 51 | 15.6% |
| Travel and Lodging | $39,259 | 118 | 4.1% |
| Food and Beverage | $30,331 | 1,125 | 3.1% |
| Honoraria | $7,700 | 1 | 0.8% |
| Education | $573.09 | 9 | 0.1% |
Payments by Type
General
$673,743
1,482 transactions
Research
$292,379
92 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $250,020 | 155 | $0 (2023) |
| Lilly USA, LLC | $247,986 | 243 | $0 (2024) |
| PFIZER INC. | $174,913 | 163 | $0 (2024) |
| ABBVIE INC. | $120,071 | 231 | $0 (2024) |
| UCB, Inc. | $41,363 | 61 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $27,060 | 103 | $0 (2024) |
| Janssen Research & Development, LLC | $23,022 | 10 | $0 (2024) |
| Horizon Therapeutics plc | $13,774 | 3 | $0 (2020) |
| Eli Lilly Export S.A. Puerto Rico Branch | $11,238 | 1 | $0 (2017) |
| DERMIRA, INC. | $10,191 | 6 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $61,830 | 165 | UCB, Inc. ($23,741) |
| 2023 | $134,066 | 226 | PFIZER INC. ($88,197) |
| 2022 | $123,905 | 210 | Lilly USA, LLC ($63,761) |
| 2021 | $43,903 | 145 | PFIZER INC. ($11,620) |
| 2020 | $56,921 | 95 | Eli Lilly and Company ($21,345) |
| 2019 | $158,879 | 216 | Eli Lilly and Company ($80,391) |
| 2018 | $210,817 | 261 | Eli Lilly and Company ($92,807) |
| 2017 | $175,799 | 256 | AbbVie, Inc. ($79,224) |
All Payment Transactions
1,574 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $36.47 | General |
| Category: Immunology | ||||||
| 12/19/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | Winlevi (Drug) | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: Dermatology | ||||||
| 12/18/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $22.94 | General |
| Category: DERMATOLOGY | ||||||
| 12/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.89 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | CIBINQO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,275.00 | General |
| Category: Inflammation & Immunology | ||||||
| 12/11/2024 | PFIZER INC. | CIBINQO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Inflammation & Immunology | ||||||
| 12/11/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $11.48 | General |
| Category: Dermatology | ||||||
| 12/02/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $48.49 | General |
| Category: DERMATOLOGY | ||||||
| 11/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $5.65 | General |
| Category: Dermatology | ||||||
| 11/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $5.44 | General |
| Category: Dermatology | ||||||
| 11/14/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $42.02 | General |
| Category: Immunology | ||||||
| 11/12/2024 | UCB, Inc. | Bimzelx (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Immunology | ||||||
| 11/11/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $19.36 | General |
| Category: Immunology | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $27.38 | General |
| Category: Immunology | ||||||
| 11/07/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Inflammation & Immunology | ||||||
| 11/06/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $1.74 | General |
| Category: Dermatology | ||||||
| 11/05/2024 | Dermavant Sciences, Inc. | VTAMA (Drug) | Food and Beverage | In-kind items and services | $25.97 | General |
| Category: DERMATOLOGY | ||||||
| 10/31/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $22.47 | General |
| Category: IMMUNOLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $24.23 | General |
| Category: IMMUNOLOGY | ||||||
| 10/29/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $44.49 | General |
| Category: Immunology | ||||||
| 10/24/2024 | Novartis Pharmaceuticals Corporation | COSENTYX (Drug) | Food and Beverage | In-kind items and services | $19.85 | General |
| Category: Dermatology | ||||||
| 10/23/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $18.00 | General |
| Category: Dermatology | ||||||
| 10/17/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.21 | General |
| Category: Immunology | ||||||
| 10/17/2024 | PFIZER INC. | CIBINQO (Drug), LITFULO | Food and Beverage | In-kind items and services | $9.47 | General |
| Category: Inflammation & Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $59,818 | 13 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $47,572 | 5 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $41,660 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA | Eli Lilly and Company | $31,906 | 5 |
| A MULTICENTER, OPEN-LABEL, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $16,379 | 5 |
| ABROCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $13,050 | 10 |
| A MULTICENTER, LONG-TERM EXTENSION TO EVALUATE THE LONG-TERM SAFETY AND MAINTENANCE OF TREATMENT EFFECT OF LY3074828 IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-3 | Eli Lilly and Company | $12,733 | 5 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $11,988 | 4 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly Export S.A. Puerto Rico Branch | $11,238 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES | Eli Lilly and Company | $6,944 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $5,316 | 4 |
| RITLECITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,800 | 4 |
| CC-10004-PSOR-012 | Celgene Corporation | $3,785 | 1 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH PSORIASIS | Eli Lilly and Company | $3,277 | 3 |
| BREPOCITINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| ZIMLOVISERTIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| A PHASE 1, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SUBCUTANEOUS LY3471851 IN PATIENTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $2,504 | 2 |
| PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $2,500 | 1 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $1,988 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE ALOPECIA AREATA | Eli Lilly and Company | $1,860 | 3 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | Regeneron Pharmaceuticals, Inc. | $1,293 | 1 |
| DUPIXENT CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,278 | 3 |
| PHASE 1, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, TRIPLE-BLIND, SINGLE-ASCENDING DOSE AND REPEAT-DOSE TRIAL IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS | Eli Lilly and Company | $1,028 | 3 |
| CC-10004-PSOR-012 - A Phase 4, Multicenter, Randomized, Placebo-controlled, Double-blind, Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects with Moderate Plaque Psoriasis | Celgene Corporation | $967.00 | 1 |
| An Open-label Study of Dupilumab in Patients With Atopic Dermatitis Who Participated in Previous Dupilumab Clinical Trials | SANOFI-AVENTIS U.S. LLC | $717.04 | 2 |
| A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris | Valeant Pharmaceuticals North America LLC | $484.00 | 1 |
| JAK INHIBITOR DERM CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BARICITINIB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $191.15 | 1 |
| OLE | SANOFI-AVENTIS U.S. LLC | $177.85 | 1 |
| An Open-Label, Drug-Drug Interaction Study to Examine the Effects of Dupilumab on the Pharmacokinetics of Selected Cytochrome P450 Substrates in Adult Patients With Moderate to Severe Atopic Dermatitis | Regeneron Pharmaceuticals, Inc. | $70.94 | 2 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $66.70 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3041658 IN ADULTS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA | Eli Lilly and Company | $60.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 2,113 | 4,347 | $450,302 | $150,818 |
| 2022 | 12 | 2,130 | 3,522 | $733,388 | $165,654 |
| 2021 | 14 | 2,090 | 6,038 | $865,902 | $213,091 |
| 2020 | 16 | 2,301 | 5,243 | $584,425 | $209,088 |
Total Patients
8,634
Total Services
19,150
Medicare Billing
$738,652
Procedure Codes
59
All Medicare Procedures & Services
59 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 633 | 931 | $166,849 | $55,143 | 33.0% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 369 | 554 | $73,363 | $21,923 | 29.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 185 | 216 | $42,951 | $15,005 | 34.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 166 | 179 | $39,804 | $13,805 | 34.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 107 | 149 | $37,861 | $13,669 | 36.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 298 | 1,887 | $24,316 | $8,791 | 36.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 82 | 82 | $18,385 | $5,827 | 31.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 98 | 109 | $12,204 | $4,741 | 38.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 55 | 81 | $7,972 | $3,132 | 39.3% |
| 10040 | Acne surgery | Office | 2023 | 20 | 21 | $4,814 | $1,755 | 36.5% |
| 17261 | Destruction of cancer skin growth of trunk, arms, or legs, 0.6-1.0 cm | Office | 2023 | 15 | 18 | $5,256 | $1,737 | 33.0% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 14 | 14 | $4,682 | $1,730 | 36.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 14 | 14 | $4,658 | $1,699 | 36.5% |
| 69100 | Biopsy of ear | Office | 2023 | 16 | 18 | $3,447 | $883.87 | 25.6% |
| 11900 | Injection into skin growth, 1-7 growths | Office | 2023 | 14 | 17 | $1,921 | $554.65 | 28.9% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 12 | 12 | $1,722 | $394.03 | 22.9% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 15 | 45 | $97.34 | $29.05 | 29.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 347 | 491 | $188,544 | $42,855 | 22.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 483 | 639 | $174,447 | $39,406 | 22.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 370 | 589 | $118,978 | $23,248 | 19.5% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 249 | 307 | $93,942 | $22,115 | 23.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 133 | 139 | $46,982 | $11,407 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 55 | 55 | $27,885 | $6,946 | 24.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 77 | 77 | $26,180 | $6,013 | 23.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 287 | 1,055 | $21,100 | $5,089 | 24.1% |
About Dr. Seth Forman, MD
Dr. Seth Forman, MD is a Dermatopathology healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/21/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346304540.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Seth Forman, MD has received a total of $966,121 in payments from pharmaceutical and medical device companies, with $61,830 received in 2024. These payments were reported across 1,574 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($444,777).
As a Medicare-enrolled provider, Forman has provided services to 8,634 Medicare beneficiaries, totaling 19,150 services with total Medicare billing of $738,652. Data is available for 4 years (2020–2023), covering 59 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatopathology
- Other Specialties Procedural Dermatology, Dermatology
- Location Tampa, FL
- Active Since 12/21/2006
- Last Updated 09/12/2019
- Taxonomy Code 207ND0900X
- Entity Type Individual
- NPI Number 1346304540
Products in Payments
- TALTZ (Drug) $193,049
- Humira (Biological) $79,400
- NURTEC ODT (Drug) $62,318
- CIBINQO (Drug) $47,594
- Olumiant (Drug) $36,000
- Bimzelx (Biological) $29,219
- COSENTYX (Biological) $26,564
- LITFULO (Drug) $17,523
- KRYSTEXXA (Biological) $13,774
- OLUMIANT (Drug) $10,190
- QBREXZA (Drug) $10,164
- Otezla (Drug) $5,274
- Cimzia (Drug) $5,047
- Tremfya (Drug) $4,734
- DUPIXENT (Biological) $3,317
- XEOMIN (Biological) $1,638
- SKYRIZI (Biological) $1,452
- RINVOQ (Biological) $1,084
- DUPIXENT (Drug) $991.03
- EUCRISA (Drug) $804.59
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatopathology Doctors in Tampa
Dr. John Millns, M.d, M.D
Dermatopathology — Payments: $9,872
Dermatopathology $9,872
Dr. Mustafa Mohammad, M.d, M.D
Dermatopathology — Payments: $2,580
Dermatopathology $2,580
Isabel Valencia, Md, MD
Dermatopathology — Payments: $2,444
Dermatopathology $2,444
Dr. William Eng, Md, MD
Dermatopathology — Payments: $1,311
Dermatopathology $1,311
Lewis Glass, Md, MD
Dermatopathology — Payments: $932.66
Dermatopathology $932.66
Rachel Careccia, M.d, M.D
Dermatopathology — Payments: $577.29
Dermatopathology $577.29